The biotechnology industry in the US is a dynamic sector focused on developing innovative solutions in medicine and agriculture. Companies range from small startups leveraging genetic engineering to large pharmaceutical corporations creating advanced therapies. This industry has seen rapid advancements, especially in gene editing and personalized medicine, driven by the integration of technology and biological research. With an increasing emphasis on sustainability and efficient healthcare solutions, biotech is expected to grow even more vital in addressing global challenges, fostering health revolution, food security, and environmental resilience. By pioneering breakthroughs, this industry holds promise for improved quality of life.


The investors featured in this list represent an amalgamation of venture capital firms, corporate giants, and private equity players, primarily based in major US cities such as New York and San Francisco. Ranging from well-established entities that have been around since the late 1800s to newer firms founded in the past decade, their collective focus is on innovative biotechnology ventures. In total, these investors made 571 deals in 2024, demonstrating robust engagement in the biotechnology sector, further bolstering the landscape with their financial backing and strategic insights.


Top 19 Biotechnology Investors in the US


1. OrbiMed

  • Website: orbimed.com
  • Type: Venture Capital
  • Headquarters: New York, New York, United States (USA)
  • Founded year: 1989
  • Headcount: 51-200
  • Number of deals in 2024: 52
  • LinkedIn: orbimed-advisors

OrbiMed is an investment firm specializing in healthcare investments, founded in 1989 and based in New York, New York. With approximately $17 billion in assets under management, OrbiMed focuses on providing capital to companies engaged in biopharmaceuticals, medical devices, and healthcare services. The firm has been involved in notable transactions within the biotechnology sector, including leading a $70 million Series B financing for Intellia Therapeutics, which is focused on gene editing technologies. Additionally, OrbiMed led a $105 million Series B funding round for AbCellera, a company that has developed a platform for antibody discovery. These investments highlight OrbiMed's commitment to driving innovation in the biotechnology industry, making it a key player in the healthcare investment landscape.


2. Perceptive Advisors


Perceptive Advisors is a New York-based venture capital firm founded in 1999, specializing in the life sciences sector. The firm provides capital solutions and investment management services to both private and public healthcare companies, with a strong emphasis on biotechnology, pharmaceuticals, and medical devices. Notable transactions include a $260 million investment in Beam Therapeutics, a company focused on gene editing technologies, and a $40 million investment in Precision BioSciences, which is known for its innovative gene-editing platform. Additionally, Perceptive Advisors participated in funding rounds for Alector, a biotech company developing immune-modulating drugs for neurodegenerative disorders. These investments highlight their commitment to supporting innovation and growth within the biotechnology industry.


3. Y Combinator

  • Website: ycombinator.com
  • Type: Venture Capital
  • Headquarters: San Francisco, California, United States (USA)
  • Founded year: 2005
  • Headcount: 51-200
  • Number of deals in 2024: 802
  • LinkedIn: y-combinator

Y Combinator is a prominent startup accelerator and venture capital firm based in San Francisco, California, founded in 2005. It provides funding and mentorship to early-stage technology companies through a structured program that includes resources like the Startup School and co-founder matching services. With over 4,000 startups launched, Y Combinator has established itself as a key player in the technology startup ecosystem. Notably, Y Combinator has made significant investments in the biotechnology sector, including a $10 million Series A financing round for Shasqi, which is focused on GMP manufacturing and Phase 1 human trials. Additionally, it has invested in Talus Bio, which raised $11.2 million in a Seed Round in 2024, further demonstrating its commitment to supporting innovative biotechnology ventures. Other investments include Invitris and Abalone Bio, which also highlight Y Combinator's engagement in the biotechnology field.


4. Sosv

  • Website: sosv.com
  • Type: Venture Capital
  • Headquarters: United States (USA)
  • Founded year: 1995
  • Headcount: 51-200
  • Number of deals in 2024: 170
  • LinkedIn: sosv

SOSV is a venture capital firm founded in 1995, specializing in funding and supporting deep tech startups through its development programs. With a global reach, SOSV connects innovative companies with investors, providing not only venture capital investment but also essential resources to help startups grow and succeed. In the biotechnology sector, SOSV has made notable investments, including Serenity Bioworks, which raised funds through convertible notes and seed rounds in 2018 and 2019, and Proteinea, which secured funding in 2021 and 2022 through convertible notes. Additionally, they invested in Karma Biotechnologies in 2023 during its seed round. These transactions highlight SOSV's active role in the biotechnology industry, reinforcing its position as a significant player in this field.


5. ARCH Venture Partners

  • Website: archventure.com
  • Type: Venture Capital
  • Headquarters: Chicago, Illinois, United States (USA)
  • Founded year: 1986
  • Headcount: 11-50
  • Number of deals in 2024: 32
  • LinkedIn: arch-venture-partners

ARCH Venture Partners is a venture capital firm based in Chicago, Illinois, founded in 1986. The firm specializes in biotechnology investments, providing funding and strategic support to innovative companies in the life sciences sector. They primarily target early-stage biotech firms that are developing groundbreaking medical solutions. Notable transactions include a $24.6 million investment in Alnylam Pharmaceuticals in 2003, which focuses on RNA interference therapeutics, and significant funding rounds for Beam Therapeutics, including $87 million in Series A and $135 million in Series B financing, aimed at advancing CRISPR technology. Additionally, ARCH has invested in Vir Biotechnology, contributing to their $150 million venture round in 2017 and $327.6 million Series B in 2019, which focuses on developing therapies for infectious diseases. These transactions highlight ARCH's active engagement in the biotechnology sector and their commitment to fostering innovation in this field.


6. Casdin Capital, LLC

  • Website: casdincapital.com
  • Type: Venture Capital
  • Headquarters: New York, New York, United States (USA)
  • Founded year: 2012
  • Headcount: 11-50
  • Number of deals in 2024: 9
  • LinkedIn: casdin-capital-llc

Casdin Capital, LLC is a New York-based venture capital firm founded in 2012, specializing in the life sciences sector. The firm focuses on investing in healthcare, biotechnology, synthetic biology, and technology, providing funding and strategic partnerships to innovative companies. Notable transactions include a $260 million investment in Beam Therapeutics, a leader in gene editing technology, and participation in funding rounds for Editas Medicine, a CRISPR-focused company, and Decibel Therapeutics, which is advancing therapies for hearing loss. Casdin Capital's investments support the research and development efforts of companies aiming to make significant advancements in biotechnology and healthcare.


7. Pfizer

  • Website: pfizer.com
  • Type: Corporate
  • Headquarters: New York, New York, United States (USA)
  • Founded year: 1849
  • Headcount: 10001+
  • Number of deals in 2024: 10
  • LinkedIn: pfizer

Pfizer Inc. is a leading pharmaceutical and biotechnology company based in New York, founded in 1849. The company develops and produces a diverse array of medicines and vaccines aimed at improving patient health outcomes globally. In 2023, Pfizer announced a significant acquisition of Seagen, a biotechnology company focused on cancer therapies, for $31 billion, highlighting its strategic interest in expanding its biotechnology portfolio. Additionally, Pfizer Ventures has participated in funding rounds for biotechnology firms such as Kymera Therapeutics, contributing to their Series B and Series C financing rounds, which are aimed at advancing clinical development in oncology and immunology. Pfizer's involvement in these transactions underscores its active role in the biotechnology sector, further solidifying its position as a key investor in this field.


8. Invus

  • Website: invus.com
  • Type: Venture Capital
  • Headquarters: New York, New York, United States (USA)
  • Founded year: 1985
  • Headcount: 51-200
  • Number of deals in 2024: 35
  • LinkedIn: invus

Invus is a venture capital investment firm based in New York, founded in 1985, specializing in equity investments and investment management. The firm partners with owner-managers across various industries to enhance business performance and create sustainable value, focusing on long-term growth. Invus has been involved in several significant transactions within the biotechnology sector, including a $450 million investment in Moderna Therapeutics, which was the largest private fundraising round for any biotechnology company at the time. They also participated in a $115 million Series C financing round for Caribou Biosciences, aimed at advancing CRISPR technology and immune cell therapies. Additionally, Invus has invested in BioNTech, contributing to both their Series A and Series B funding rounds, which supported the development of their therapeutics pipeline. These transactions highlight Invus's active role in the biotechnology industry, alongside their broader investment strategy.


9. Janus Henderson Investors

  • Website: janushenderson.com
  • Type: Private Equity
  • Headquarters: Denver, Colorado, United States (USA)
  • Founded year: 2017
  • Headcount: 1001-5000
  • Number of deals in 2024: 39
  • LinkedIn: janus-henderson-emea

Janus Henderson Investors is a private equity firm based in Denver, Colorado, founded in 2017. The firm specializes in asset management, offering a diverse range of investment products including ETFs, mutual funds, and managed accounts. With a global presence and a focus on disciplined investment strategies, Janus Henderson serves individual investors, financial professionals, and institutional clients. In the biotechnology sector, Janus Henderson has made notable investments, including participation in a $102 million Series C financing for Kymera Therapeutics, a $40 million post-IPO equity investment in Precision BioSciences, and involvement in the oversubscribed Series D financing for Decibel Therapeutics, which raised $82.2 million. Their investments also extend to companies like Galecto and Caribou Biosciences, showcasing their active role in supporting the development of innovative biotechnological solutions.


10. Redmile Group

  • Website: redmilegroup.com
  • Type: Venture Capital
  • Headquarters: San Francisco, California, United States (USA)
  • Founded year: 2007
  • Headcount: 11-50
  • Number of deals in 2024: 15
  • LinkedIn: redmile-group

Redmile Group is an investment management firm based in San Francisco, California, founded in 2007. The firm specializes in providing asset management and investment strategies to high-net-worth individuals and institutional investors. Redmile Group has a notable focus on the healthcare and biotechnology sectors, as evidenced by their participation in significant funding rounds for companies such as Beam Therapeutics, where they contributed to a $135 million Series B financing and a $260 million post-IPO equity round. Additionally, they were involved in Kymera Therapeutics' $102 million Series C financing and a $150 million private placement equity financing. Their investments also extend to Wave Life Sciences, where they participated in a $66 million Series B financing. These transactions highlight Redmile Group's active role in supporting the development of innovative biotechnological solutions and therapies.


11. New Enterprise Associates (NEA)

  • Website: nea.com
  • Type: Venture Capital
  • Headquarters: Menlo Park, California, United States (USA)
  • Founded year: 1977
  • Headcount: 51-200
  • Number of deals in 2024: 57
  • LinkedIn: new-enterprise-associates

New Enterprise Associates (NEA) is a venture capital firm founded in 1977, based in Menlo Park, California. NEA specializes in investment management and advisory services for startups, particularly in the technology and healthcare sectors. The firm partners with entrepreneurs to provide funding and strategic guidance, helping them navigate the challenges of building successful businesses. NEA has been actively involved in the biotechnology industry, with significant investments in companies such as Seagen, CRISPR Therapeutics, and Synlogic. For instance, NEA participated in multiple funding rounds for CRISPR Therapeutics, contributing $35 million in Series A and $29 million in Series B funding. They also invested $42 million in Synlogic during its Series C round and $40 million in its Series B round. This collaborative approach emphasizes long-term relationships with founders and a commitment to advancing innovative healthcare solutions.


12. GV (Google Ventures)

  • Website: gv.com
  • Type: Venture Capital
  • Headquarters: San Francisco Bay Area, California, United States (USA)
  • Founded year: 2009
  • Headcount: 51-200
  • Number of deals in 2024: 74
  • LinkedIn: gv

GV (Google Ventures) is a venture capital firm founded in 2009, based in the San Francisco Bay Area, California. With over $10 billion in assets under management, GV focuses on various sectors, including life sciences and artificial intelligence. The firm partners with innovative technology startups, providing funding and support to help them navigate the challenges of building successful companies. Notably, GV has invested in several prominent biotechnology firms, such as Beam Therapeutics, which is advancing CRISPR technology, and Adimab, which is expanding its platform for therapeutic development. Additionally, GV has participated in funding rounds for Editas Medicine, a leader in CRISPR research, and Decibel Therapeutics, which is focused on developing therapies for hearing loss. These investments highlight GV's active role in the biotechnology sector, reinforcing its relevance as a biotechnology investor.


13. Vivo Capital

  • Website: vivocapital.com
  • Type: Venture Capital
  • Headquarters: Palo Alto, California, United States (USA)
  • Founded year: 1996
  • Headcount: 51-200
  • Number of deals in 2024: 19
  • LinkedIn: vivo-capital

Vivo Capital is a venture capital firm founded in 1996 and based in Palo Alto, California. The firm specializes in healthcare investments, providing venture capital, private equity, and public equity investments to companies in the healthcare sector. Vivo Capital has a global focus, targeting companies that develop innovative healthcare technologies and products. Notably, Vivo Capital has participated in significant funding rounds for various biotechnology companies, including leading a $70.5 million Series D funding for REGENXBIO, a gene therapy-focused biotech company. They also invested in Precision BioSciences, which raised $110 million to advance its product portfolio in immuno-oncology and gene therapy. Additionally, Vivo Capital was involved in a $120 million private placement for Silence Therapeutics, aimed at advancing clinical development of their innovative therapies. Their active participation in these transactions highlights their commitment to fostering growth and innovation within the biotechnology industry.


14. Samsara BioCapital

  • Website: samsaracap.com
  • Type: Venture Capital
  • Headquarters: Palo Alto, California, United States (USA)
  • Founded year: 2016
  • Headcount: 11-50
  • Number of deals in 2024: 27
  • LinkedIn: samsara-biocapital

Samsara BioCapital is a biotechnology investment firm based in Palo Alto, California, founded in 2016. The firm specializes in investing in innovative therapies and providing essential support to entrepreneurs in the medical field. Samsara BioCapital offers fundraising and networking guidance to help biotech companies develop and commercialize their products, primarily serving clients in the biotechnology and healthcare sectors. Notable transactions include leading the Series E financing for Sutro Biopharma, which raised $85.4 million, and participating in the Series D financing for Recursion Pharmaceuticals, which raised $239 million. They have also been involved in significant funding rounds for companies like Decibel Therapeutics and Adverum Biotechnologies, further solidifying their position as a key player in the biotechnology investment landscape.


15. Frazier Healthcare Partners


Frazier Healthcare Partners is a venture capital firm based in Seattle, Washington, founded in 1991. The firm specializes in healthcare and life sciences, focusing on growth buyout investments in profitable healthcare businesses and innovative biopharmaceuticals. With a robust portfolio, Frazier Healthcare has been involved in significant transactions within the biotechnology sector, including a post-IPO equity investment in REGENXBIO and a $144.9 million investment in Sutro Biopharma. Additionally, they participated in a $20 million post-IPO equity round for Silence Therapeutics, which is advancing clinical development for its biopharmaceutical products. Their strategic investments highlight their commitment to enhancing the capabilities of healthcare companies and supporting the advancement of biotechnology innovations.


16. EcoR1 Capital, LLC

  • Website: ecor1cap.com
  • Type: Venture Capital
  • Headquarters: San Francisco, California, United States (USA)
  • Founded year: 2012
  • Headcount: 11-50
  • Number of deals in 2024: 14
  • LinkedIn: ecor1-capital-llc

EcoR1 Capital, LLC is a San Francisco-based venture capital firm founded in 2012, specializing in biotechnology investments. The firm partners with entrepreneurs to develop innovative therapeutics, leveraging its expertise in both science and strategy to support the development of new medicines. EcoR1 Capital has been actively involved in the biotechnology sector, participating in notable transactions such as a $70 million Series B financing for Intellia Therapeutics, which focuses on gene editing, and a $150 million private placement for Kymera Therapeutics, aimed at advancing research and development. They also participated in a $120 million funding round for Editas Medicine, a leader in CRISPR technology, and a $50 million private placement for Zymeworks, which is focused on developing next-generation therapeutics. Most recently, EcoR1 co-led a $350 million private placement for Arvinas, which is advancing clinical development programs. These transactions highlight EcoR1 Capital's commitment to supporting innovative biotech companies and their potential to improve patient outcomes.


17. IndieBio

  • Website: indiebio.co
  • Type: Venture Capital
  • Headquarters: San Francisco, California, United States (USA)
  • Founded year: 2015
  • Headcount: 1-10
  • Number of deals in 2024: 76
  • LinkedIn: indiebio

IndieBio is a venture capital firm founded in 2015 and based in San Francisco, California. It specializes in biotechnology and is dedicated to supporting startups by providing investment, mentorship, and networking opportunities. IndieBio focuses on helping biotech entrepreneurs develop innovative solutions across various sectors, including climate and food. Notable transactions include investments in Serenity Bioworks, which raised funds through convertible notes and seed rounds, and Proteinea, which also secured funding via convertible notes. These transactions highlight IndieBio's commitment to advancing biotechnology innovations and supporting the growth of startups in this critical industry.


18. Rock Springs Capital

  • Website: rockspringscapital.com
  • Type: Venture Capital
  • Headquarters: Baltimore, Maryland, United States (USA)
  • Founded year: 2013
  • Headcount: 51-200
  • Number of deals in 2024: 16
  • LinkedIn: knectit

Rock Springs Capital is a venture capital investment firm based in Baltimore, Maryland, founded in 2013. The firm specializes in investment management and related financial services, catering to clients seeking asset management solutions. Rock Springs Capital has been involved in several notable transactions within the biotechnology sector, including a $140 million post-IPO equity investment in Immunocore in July 2022, which focuses on developing innovative therapies for cancer and other diseases. They also participated in a $130 million Series B financing round for Immunocore in March 2020, aimed at expanding their scientific platform. Additionally, Rock Springs Capital was part of a $72.8 million Series B financing for Spark Therapeutics in May 2014, which is known for its gene therapy programs. Furthermore, they contributed to a $150 million private placement equity financing for Kymera Therapeutics in August 2022, supporting ongoing research and development activities. These transactions highlight Rock Springs Capital's active role in the biotechnology industry, particularly in funding companies that are pioneering advancements in healthcare.


19. F-Prime


F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, founded in 1946. The firm specializes in creating and investing in healthcare and technology companies, providing both venture capital investments and advisory services to entrepreneurs. F-Prime has a global presence and expertise that enables it to effectively support start-ups in developing innovative solutions. Notably, F-Prime has participated in significant funding rounds for biotechnology companies, including Beam Therapeutics, where it was involved in both Series A and Series B financing rounds aimed at advancing CRISPR technology. Additionally, F-Prime invested in Precision BioSciences, which focuses on genome editing and has raised substantial funds to accelerate its product portfolio in immuno-oncology and genetic diseases. These transactions highlight F-Prime's active role in the biotechnology sector, reinforcing its commitment to fostering innovation in healthcare.



Biotechnology Insights: Key Investors in the US


InvestorHeadquarterSizeFoundedDeals 2024
OrbiMedNew York, New York, United States (USA)51-200198952
Perceptive AdvisorsNew York, New York, United States (USA)11-50199945
Y CombinatorSan Francisco, California, United States (USA)51-2002005802
SosvUnited States (USA)51-2001995170
ARCH Venture PartnersChicago, Illinois, United States (USA)11-50198632
Casdin Capital, LLCNew York, New York, United States (USA)11-5020129
PfizerNew York, New York, United States (USA)10001+184910
InvusNew York, New York, United States (USA)51-200198535
Janus Henderson InvestorsDenver, Colorado, United States (USA)1001-5000201739
Redmile GroupSan Francisco, California, United States (USA)11-50200715
New Enterprise Associates (NEA)Menlo Park, California, United States (USA)51-200197757
GV (Google Ventures)San Francisco Bay Area, California, United States (USA)51-200200974
Vivo CapitalPalo Alto, California, United States (USA)51-200199619
Samsara BioCapitalPalo Alto, California, United States (USA)11-50201627
Frazier Healthcare PartnersSeattle, Washington, United States (USA)51-200199127
EcoR1 Capital, LLCSan Francisco, California, United States (USA)11-50201214
IndieBioSan Francisco, California, United States (USA)1-10201576
Rock Springs CapitalBaltimore, Maryland, United States (USA)51-200201316
F-PrimeCambridge, Massachusetts, United States (USA)11-50194639


Want to find more investors focusing on the biotechnology industry?

If you want to find more investors that are active in the biotechnologyindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!